询 价
索取COA
产品描述
产品数据库
Introduction | |||||||
Format | Genomic DNA | ||||||
Description | In terms of mechanism of action, tumor cells with HRD are more sensitive to platinum drugs or PARP inhibitors. In ovarian cancer, BRCA gene mutation, HRR gene mutation, gene promoter methylation, and other reasons can all cause HRD. HRD testing may provide opportunities for benefit for BRCA-negative patients. HRD positive is a reasonable biomarker for choosing maintenance therapy with PARP inhibitors. | ||||||
Catalog ID | Sample | 匹配度 | HRD Score | 药敏 | HRR | 备注 | COA下载 |
CBP90023-1 | HRD-P1 | 0.86 | Positive -High | 78.4 | 500x WES分享 | 配对样本 | 请点击下载 |
CBP90023-2 | HRD-P2 | 0.84 | Positive -High | 33.73 | 500x WES分享 | 配对样本 | 请点击下载 |
CBP90023-9 | HRD-P9 | 0.9 | Positive-High | N/A | 500x WES分享 | 配对样本 | 请点击下载 |
CBP90023-3 | HRD-P3 | 0.8 | Positive-High | 144.54 | 500x WES分享 | 配对样本 | 请点击下载 |
CBP90023-4 | HRD-P4 | 0.83 | Critical Value-Median | 67.9 | 500x WES分享 | 配对样本 | 请点击下载 |
CBP90023-15 | HRD-P15 | 0.88 | Critical Value-Median | N/A | 500x WES分享 | 配对样本 | 请点击下载 |
CBP90023-10 | HRD-P10 | 0.92 | Negative-Low | 100 | 500x WES分享 | 配对样本 | 请点击下载 |
CBP90023-13 | HRD-P13 | 0.95 | Negative-Low | 2.14 | 500x WES分享 | 配对样本 | 请点击下载 |
Product Information | |||||||
Intended Use | Research Use Only | ||||||
Unit Size | 1ug/vial * 2 vial | ||||||
Concentration | Download for COA | ||||||
Purity | Download for COA | ||||||
DNA electrophoresis | Download for COA | ||||||
Storage | 2-8℃ | ||||||
Expiry | 36 months from the date of manufacture |